Company Overview of Cima Labs Inc.
Cima Labs Inc. engages in the research and development (R&D), formulation, manufacturing, and packaging of drug delivery technologies for pharmaceutical companies in the United States and internationally. The company specializes in orally disintegrating tablet (ODT), oral trans-mucosal (OTM), and oral powder drug delivery technologies. It offers ODTs, such as OraSolv, a technology that delivers taste-masked drug micro particles through a formulation, which enhances tablet disintegration; DuraSolv, a technology, which produces an ODT that combines taste-masked active drug ingredients with or without a low effervescence system; and Lyoc, a technology that lyophilizes or freeze-dries an aqueous...
7325 Aspen Lane
Brooklyn Park, MN 55428
Founded in 1986
Key Executives for Cima Labs Inc.
Vice President of Drug Delivery Technologies
Senior Director of Regulatory Affairs & Project Management
Senior Director of Analytical Development
Compensation as of Fiscal Year 2014.
Cima Labs Inc. Key Developments
CIMA LABS INC. Presents at EBD Group's 7th Annual BIO-Europe Spring Conference 2013, Mar-11-2013
Feb 7 13
CIMA LABS INC. Presents at EBD Group's 7th Annual BIO-Europe Spring Conference 2013, Mar-11-2013 . Venue: Centre Covencions International Barcelona, Plaça de Willy Brandt, 11-14, 08019 Barcelona, Spain.
Mylan, Inc. Enters into Settlement Agreement with Cima Labs, Inc. and Shionogi Inc
Oct 9 12
Mylan, Inc. announced that it has entered into a settlement agreement with Shionogi Inc. and Cima Labs, Inc. that will resolve patent litigation related to Prednisolone Sodium Phosphate Orally Disintegrating Tablets (ODT), 10 mg, 15 mg and 30 mg. Prednisolone Sodium Phosphate ODT is the generic version of Shionogi's Orapred ODT(R), which is indicated for the treatment of certain pulmonary diseases such as asthma. Additionally, the product is indicated for the control of certain severe or incapacitating allergic conditions, such as atopic dermatitis, and seasonal and perennial allergic rhinitis, that are intractable to adequate trials of conventional treatment. According to the terms of the settlement, Mylan will be licensed to sell its Prednisolone Sodium Phosphate ODT product on April 1, 2014, or earlier under certain circumstances. Pursuant to the agreement, pending litigation will be dismissed. Other details of the settlement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|